<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Centre for Molecular Medicine</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F7E13617-2678-475B-99E4-31479C92038D"><gtr:id>F7E13617-2678-475B-99E4-31479C92038D</gtr:id><gtr:name>University of Aberdeen</gtr:name><gtr:address><gtr:line1>University Office</gtr:line1><gtr:line2>Regent Walk</gtr:line2><gtr:line4>Aberdeen</gtr:line4><gtr:line5>Aberdeenshire</gtr:line5><gtr:postCode>AB24 3FX</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8AFADE5F-158E-4944-8513-3AAA7C83A206"><gtr:id>8AFADE5F-158E-4944-8513-3AAA7C83A206</gtr:id><gtr:firstName>Omar</gtr:firstName><gtr:surname>Albagha</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1E9ED8CE-0D66-4BCB-8CC9-91B5A698F8BA"><gtr:id>1E9ED8CE-0D66-4BCB-8CC9-91B5A698F8BA</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Ralston</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800933"><gtr:id>AE0C674C-CA5F-4A54-B842-0425990455D9</gtr:id><gtr:title>Characterisation and therapeutic intervention of two novel mouse models of Paget's disease of bone</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800933</gtr:grantReference><gtr:abstractText>Paget?s disease (PDB) is a common bone disease that affects about 3% of people over the age of 55 in the UK which causes pain, softening of the bones, deafness and arthritis. Genetic factors are important in the disease and two abnormal genes have been discovered. It is unclear how these faulty genes cause PDB and it is also unclear if treatment might be able to protect against disease complications if given early enough. The aim of this project is to develop an experimental model for PDB in order to find out more about why the disease occurs and to determine if early treatment might be effective in preventing complications. If our experiments are successful the information gained from these studies will be used to help design clinical trials of preventative therapy in patients with the faulty genes.</gtr:abstractText><gtr:technicalSummary>Paget?s disease of bone (PDB) is a common disorder that affects up to 3.1% of individuals over the age of 55 in the UK. Paget?s disease seriously impacts on quality of life by causing bone pain, deformity, deafness, osteoarthritis and pathological fractures. Genetic factors are important in PDB. Mutations in the TNFRSF11A gene which encodes RANK cause a severe early onset type of PDB and related syndromes of familial expansile osteolysis and expansile skeletal hyperphosphatasia. Mutations in the SQSTM1 gene which encodes p62, a scaffold protein in the NFkB pathway, have been found to be an important cause of classical PDB accounting for up to 40% of familial and 11% of sporadic cases. Antiresorptive drugs have been widely used in the treatment of PDB and are effective at suppressing metabolic activity. However, these drugs have a limited impact on complications and morbidity, probably because the disease is usually far advanced by the time treatment is commenced. In view of this, there is a need to develop a disease model for PDB with which to explore the effects of early intervention to determine if this might be effective in preventing lesion development, since patients at risk of PDB with the above mutations can now be identified by genetic testing. We have recently developed two mouse models of PDB which carry a truncating mutation in SQSTM1 and a duplication mutation in TNFRSF11A. Preliminary analysis showed that these mice develop focal osteolytic lesions characteristic of PDB. Therefore, the mutant mice may represent the first animal models of PDB. The aim of this project is to use these animal models to investigate the cellular and molecular mechanisms by which these mutations affect bone cell function to cause osteolytic lesions. We will also study the possible role of environmental factors on disease development focusing on dietary calcium deficiency which has been implicated in disease severity in humans. Finally we will determine if prophylactic intetion with antiresorptive drugs can prevent the development of osteolytic lesions in these mice. The study will increase our understanding of the molecular pathways involved in the pathogenesis of PDB and provide an invaluable tool to determine disease progression and therapeutic responses.</gtr:technicalSummary><gtr:fund><gtr:end>2012-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>363782</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Aberdeen</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Medical Sciences</gtr:department><gtr:description>Analysis of bone lesions using electron microscopy</gtr:description><gtr:id>9ABDEE25-330F-4684-96D3-D9D2398CFF0F</gtr:id><gtr:impact>The work is still in near completion and output is being prepared for submission for publication.</gtr:impact><gtr:outcomeId>sDv1uvaUDHU-1</gtr:outcomeId><gtr:partnerContribution>The collaborators will contribut to the analysis of osteolytic bone lesions using electron microscopy.</gtr:partnerContribution><gtr:piContribution>Our contribution was to provide bone samples from our Paget's disease models for analysis using electron microscopy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Presentation at the Spanish Society for Bone and Mineral Research (SEIOMM)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>073740A0-259F-4517-813A-AAD51C05F716</gtr:id><gtr:impact>500 participants attended which stimulated discussions and questions afterwards.

None</gtr:impact><gtr:outcomeId>pKHN2vpNVNS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>Travel Award/European Calcified Tissue Society</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>European Calcified Tissue Society (ECTS)</gtr:fundingOrg><gtr:id>463F0C98-EA9B-4E8A-929A-DF5F63B1692C</gtr:id><gtr:outcomeId>SkFrEnCpWGd0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1493545</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>European Research Council starting grant</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:fundingRef>311723-GENEPAD</gtr:fundingRef><gtr:id>5078BB31-B576-4DA4-AF34-BF45F3E96226</gtr:id><gtr:outcomeId>i55jp6LUH3y</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Two mouse models mimicking Paget's disease of bone were generated. The first model was generated by genetic modification of the RANK gene which causes early-onset form of Paget's disease in human. The second model was generated by genetic modification of the SQSTM1 gene which causes classical Paget's disease of bone.</gtr:description><gtr:id>12C1DBA4-A7B9-4E74-9598-AE3BC9E4DEC3</gtr:id><gtr:impact>Since PDB is a late-onset disease and evolves over several decades, it is difficult to investigate the natural history of PDB in clinical studies. It is similarly difficult to determine whether or not early intervention with disease modifying therapy might favourably influence the course of the disease. Therefore, PDB is an ideal candidate to be investigated in animal models. In view of this, we have developed these two models for severe PDB to investigate disease mechanism and study if early therapeutic interventions prevent progression of the disease.</gtr:impact><gtr:outcomeId>E6FZZoStQar</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mouse Models of Paget's disease of bone</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5076628E-97F2-48A5-A311-61C5D517D733</gtr:id><gtr:title>A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349a6520453abc0255e594b7cdcddd51"><gtr:id>349a6520453abc0255e594b7cdcddd51</gtr:id><gtr:otherNames>Daroszewska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_12922_22_21515589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8470BFFB-203E-46BC-88FE-735F5D0DF58B</gtr:id><gtr:title>Genetic determinants of Paget's disease of bone.</gtr:title><gtr:parentPublicationTitle>Annals of the New York Academy of Sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f531ed5788ca5392a31198dee35e67b9"><gtr:id>f531ed5788ca5392a31198dee35e67b9</gtr:id><gtr:otherNames>Ralston SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0077-8923</gtr:issn><gtr:outcomeId>pm_12922_22_22172040</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800933</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>